Bioequivalence Evaluation of Two Atenolol Tablet Preparations in Korean Healthy Male Volunteers

  • Published : 2007.09.30


This study was conducted to compare the bioavailability of two brands of atenolol (50 mg) tablets, which are a generic product of $Ditent^{\circledR}$ (Daewon Pharmaceutical Co., Ltd., Korea) and an innovator product $Tenormin^{\circledR}$ (Hyundai Pharm. Ind. Co., Ltd., Korea), in 20 healthy Korean male volunteers. The volunteers received a single 50 mg dose of each atenolol formulation according to a randomized, two-way cross-over design. The washout period between treatments was 1 week. Plasma samples were obtained over a 24-hour interval, and atenolol concentrations were determined by HPLC with a fluorescence detector. From the plasma atenolol concentration vs. time curves, the following parameters were compared: area under the plasma concentration-time curve ($AUC_{0-24}$), peak plasma concentration ($C_{max}$), time to reach peak plasma concentration ($T_{max}$), and terminal first order elimination half-life ($t_{1/2}$). No statistically significant difference was obtained between the $T_{max}$ values, and the logarithmic transformed $AUC_{0-24}$ and $C_{max}$ values of the two products. The 90% confidence interval for the ratio of the logarithmically transformed AUC and $C_{max}$ values of $Ditent^{\circledR}$ over those of $Tenormin^{\circledR}$ were calculated to be between 0.85 and 1.04, and 0.89 and 1.07, respectively; both were within the bioequivalence limit of 0.80-1.25. The mean of $T_{max}$ in $Tenormin^{\circledR}$ group was 3.1 hour, and that in Ditent$^{\circledR}$ group was 3.2 hour. The values of $t_{1/2}$ between the two products were found comparable, and the mean values were 5.2 hour in the both products. Based on these results, it was concluded that $Ditent^{\circledR}$ was comparable to $Tenormin^{\circledR}$ in both the rate and extent of absorption, indicating that $Ditent^{\circledR}$ was bioequivalent to the reference product, $Tenormin^{\circledR}$.



  1. Conway, F. J., Fitzgerald, J. D., McAinsh, J., Rowlands, D. J. and Simpson, W. J. (1976). Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66, 082), a new cardioselective beta-adrenoceptor blocking drug. Br. J. Clin. Pharmacol. 3, 267-272
  2. Endrenyi, L., Fritsch, S. and Yan, W. (1991). $C_{max}$/AUC is a clear measure than $C_{max}$ for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharmacol. 29, 394-399
  3. Fitzgerald, J. D., Ruffin, R., Smedstad, K. G., Roberts, R. and McAinsh, J. (1978). Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur. J. Clin. Pharmacol. 13, 81-89
  4. Frishman, W. H. (1982). Atenolol and timolol, two new systemic $\beta$-adrenoceptor antagonists. N. Engl. J. Med. 306, 1424-1462
  5. Hainsworth, R., Karim, F., Stoker, J. B. and Harry, J. D. (1973). The blocking effects of propranolol, practolol and ICI-66082 on the peripheral vascular responses to isoprenaline. Brit. J. Pharmacol. 48, 342-343
  6. Harms, H. H. (1976). Isoproterenol antagonism of cardioselec-tive beta adrenergic receptor blocking agents: a compara-tive study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J. Pharmacol. Exp. Ther. 199, 329-335
  7. Harry, J. D., Knapp, M. F. and Linden, R. J. (1973). The action of ICI-66082 on the heart. Brit. J. Pharmacol. 48, 340-341
  8. Heel, R. C., Brogden, R. N., Speight, T. M. and Avery, G. S. (1979). Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17, 425-460
  9. Kamas, H. T., Shiu, G. and Shah, V. P. (1991). Validation of bioanalytical methods. Pharm. Res. 8, 421-426
  10. Martins, M. L., Pierossi, M. A., Moraes, L. A., Ribeiro, W., Abbib Jr., W., Mendes, G. B., Poli, A., De Nucci, G. and Muscara, M. N. (1997). Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration. Int. J. Clin. Pharmacol. Ther. 35, 324-328
  11. Stoschitzky, K., Egginger, G., Zernig, G., Klein, W. and Lindner, W. (1993). Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic and radioligand binding studies. Chirality 5, 15-19
  12. Winkler, H., Ried, W. and Lemmer, B. (1982). Highperformance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue. J. Chromatogr. 228, 223-234
  13. Shargel L. and Yu, A. (1999). Applied Biopharmaceutics and Pharmacokinetics. Prentice Hall International, London. pp. 223-245